AstraZeneca drops another GLP-1 after phase 1 data bust market-beating diabetes hopes

Two months after dropping one of its GLP-1 agonists, AstraZeneca has decided to scrap its remaining clinical candidate. A preliminary analysis of the phase 1 data convinced the company that the drug would not outperform the competition.